-64%

est. 2Y upside i

HealthcareSeries A

We deliver personalized medicine for neurodegenerative patients

Rank

#812

Sector

Telehealth / Digital Health

Est. Liquidity

~5Y

Data Quality

Data: Medium

Synapticure operates in a large and growing market with a specialized niche in neurodegenerative virtual care, supported by a recent $25M Series A round and estimated revenues of $25M-$50M.

Last updated: March 10, 2026

Bull (23%)+350%

Synapticure rapidly expands its partnerships with major health systems and payers, leveraging its AI-enabled platform to become the dominant virtual care provider for neurodegenerative diseases. Revenue exceeds $200M by 2028, justifying a $900M valuation (4.5x current) at exit, driven by strong market penetration and a clear path to profitability.

Base (50%)+75%

Synapticure continues to grow steadily, securing additional funding rounds and expanding its patient base. It maintains its niche leadership but faces increasing competition from incumbents and specialized rivals. Revenue reaches $100M by 2028, leading to an acquisition at a $350M valuation (1.75x current), providing moderate returns for common shareholders after preferences.

Bear (27%)-80%

Increased competition from well-funded incumbents like CVS Health (potentially expanding beyond its current customer role) or specialized rivals like Harmonic Health leads to slower-than-expected growth and market share erosion. Regulatory changes or reimbursement challenges further hinder expansion. Revenue stalls below $50M, resulting in a down round or acquisition at a distressed valuation of $40M, significantly eroding common stock value due to liquidation preferences.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Investors hold $46.3M in liquidation preferences ahead of common stock, representing 23.15% of the estimated current $200M valuation.

Dilution Risk

high

As a Series A company, Synapticure will likely require multiple additional funding rounds (Series B, C, etc.) before a liquidity event, leading to significant future dilution for common shareholders.

Secondary Liquidity

none

There is currently no active secondary market for Synapticure shares, and liquidity for private company equity is generally very limited at this stage.

CARE Delivery — 10 roles

Operations — 3 roles

Finance — 1 role

Product and Technology — 1 role

View all 17 open roles at Synapticure →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Synapticure's data — designed to show you've done your homework.

  • 1

    “Given the 'medium' incumbent threat and the presence of competitors like Harmonic Health and Isaac Health, how does Synapticure plan to maintain and expand its market share against well-funded players in the next 2-3 years?”

  • 2

    “With estimated revenues between $25M-$50M and a recent Series A, what are the key milestones and growth metrics the company is focused on achieving in the next 12-18 months to prepare for future funding rounds?”

  • 3

    “Considering the $46.3M in total funding and the early stage of the company, how does Synapticure envision the timeline and potential mechanisms for a liquidity event for employees, and what are the company's strategies to mitigate future dilution?”

Community

Valuation Sentiment

Our model estimates -64% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.